US2018273914A1PendingUtilityA1

Device and method of collection for rna viruses

Assignee: GEN ELECTRICPriority: Nov 19, 2015Filed: Jun 11, 2018Published: Sep 27, 2018
Est. expiryNov 19, 2035(~9.3 yrs left)· nominal 20-yr term from priority
C12N 15/1017C12Q 1/70C12Q 2523/113B01L 3/508C12N 7/00C12N 2760/14111C12Q 2523/308C12Q 1/701B01L 2200/082C12Q 2527/125C12Q 1/6806C12N 2760/14151C12N 2760/14163
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure generally relates to a method and device for inactivation and dry storage, under ambient conditions, of a biological sample containing RNA virus. Methods for collecting and recovering RNA from a biological sample and subsequent analysis for a virus are also provided.

Claims

exact text as granted — not AI-modified
1 .- 24 . (canceled) 
     
     
         25 . A collection device for inactivation and dry storage of a biological sample containing an RNA virus without degradation of viral RNA, the device comprising:
 providing a non-dissolvable, dry, solid matrix incorporated with a composition, the composition comprising at least one protein denaturant, at least one acid or acid-titrated buffer reagent impregnated therein in a dry state;   a frame for holding the dry solid matrix; and   a storage sleeve capable of encasing the frame and dry solid matrix after collection of the sample.   
     
     
         26 . The device of  claim 25 , wherein the acid comprises acetic acid, citric acid, tartaric acid, phosphoric acid, hydrochloric acid, Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-HCl), oxidized Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-O—HCl), sulfuric acid, nitric acid, vanillic acid, 3-(N-morpholino)propanesulfonic acid or combinations thereof. 
     
     
         27 . The device of  claim 25 , where the composition further comprises a UV protectant, a free-radical scavenger, a chelator, a reducing agent or combinations thereof. 
     
     
         28 . The device of  claim 27 , where the composition further comprises an RNase inhibitor. 
     
     
         29 . The device of  claim 28  wherein the RNase inhibitor comprises at least one of a triphosphate salt, pyrophosphate salt, vanadyl ribonucleoside complex (VCR), or sodium pyrophosphate. 
     
     
         30 . The device of  claim 27 , wherein the reducing agent is selected from the group consisting of dithiothreitol (DTT), 2-mercaptoethanol (2-ME), tris(2-carboxyethyl)phosphine (TCEP), tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) and a combination thereof.

Join the waitlist — get patent alerts

Track US2018273914A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.